<DOC>
	<DOCNO>NCT03019614</DOCNO>
	<brief_summary>This open label , randomize , single dose , three period crossover pharmacokinetic study Chronocort® 30 healthy male volunteer . The study conduct small sub group ( Group 1 , n=18 Group 2 , n=12 ) .</brief_summary>
	<brief_title>An Open Label Study Healthy Volunteers Compare Chronocort® Hydrocortisone</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Healthy male volunteer 18 60 year age , inclusive ( screen ) . Subjects Body Mass Index ( BMI ) 2128 . Body Mass Index = Body weight ( kg ) / ( Height ( ) ) 2 . Subjects clinically significant abnormal serum biochemistry , haematology urine examination value within 14 day start study . The parameter measure include show Appendix 3 Study Protocol . Subjects negative urinary drug abuse screen ( include alcohol ) , determine within 14 day start study . Subjects negative HIV Hepatitis B C result . Subjects clinically significant abnormality 12lead electrocardiogram ( ECG ) determine within 14 day start study . Subjects clinicallysignificant deviation outside normal range blood pressure pulse measurement . Subjects sexual partner must use effective contraception method trial 3 month last dose , example : Oral contraceptive + condom Intrauterine device ( IUD ) + condom Diaphragm spermacide + condom Subjects must available complete study . Subjects must satisfy medical examiner fitness participate study . Subjects must provide write informed consent participate study . A clinically significant history gastrointestinal disorder likely influence drug absorption . Receipt regular medication within 14 day first study day ( include high dose vitamin , dietary supplement herbal remedy ) . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . A clinically significant history previous allergy / sensitivity Hydrocortisone . A clinically significant history drug alcohol abuse . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . Participation New Chemical Entity clinical study within previous 16 week market drug clinical study within previous 12 week . Subjects consume 2 unit alcohol per day within seven ( 7 ) day prior first dose consume alcohol within 48 hour period prior first dose . Donation 450ml blood within previous 12 week . Subjects work shift ( i.e . regularly alternated day , afternoon night ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>